Öz

Introduction: Hemoadsorption (HA) removes circulating inflammatory mediators and is used as an adjunct in septic shock. We assessed whether a protocol-based HA330 strategy improved early organ dysfunctions and outcomes.

Materials and Methods: We performed an observational study of adults with septic shock admitted to a 59-bed mixed ICU (January 2023–June 2024). We compared outcomes of patients who were treated with HA, to those who received standard of care alone.

Results: During the study period, 52 of 127 septic shock patients received hemoadsorption therapy (HA group), while 75 received standard care (control group). On ICU admission age, sex, comorbidity, APACHE II, and SOFA scores were similar. By day 3, SOFA score decreased with HA (8 [5–11] to 7 [5–9]; p<0.05) but was unchanged in controls. Vasoactive inotropic score declined in both groups, more prominently with HA. Mechanical ventilation requirement and ICU length of stay were comparable. AKI decreased from 71.2% to 46.2% in the HA but increased from 44.0% to 50.7% in the control group. Hospital stay was longer with HA (29,5 [18-47,75] vs 19 [12-30], p=0.009), whereas 28-day mortality was lower (30.8% vs 49.8%, p<0.05).

Conclusions: Protocol-based early HA at high vasopressor requirements was associated with improved organ dysfunctions and reduced 28-day mortality in septic shock patients.

Anahtar Kelimeler: hemoadsorpsiyon, septik şok, vazoaktif inotropik skor, akut böbrek hasarı, yoğun bakım ünitesi, mortalite

Etik kurul onayı

Bu çalışma Marmara Üniversitesi Tıp Fakültesi Klinik Araştırmalar Etik Kurulu tarafından onaylanmıştır(09.2024.811). Çalışmanın retrospektif olması nedeniyle yazılı bilgilendirilmiş onam alınmamıştır.

Yazarlık katkısı

Çalışma konsepti ve tasarımı: FG, MSS, BDO, AGS; veri toplama: FG, ET, EÇ, MSS, IİÇ; sonuçların analizi ve yorumlanması: FG, MSS, AGS; makaleyi hazırlama: FG, MSS, AGS. Yazar(lar) sonuçları gözden geçirmiş ve makalenin son halini onaylamıştır.

Finansman

Yazar(lar), çalışmanın herhangi bir finansal destek almadığını beyan etmiştir.

Çıkar çatışması

Yazar(lar) herhangi bir çıkar çatışması olmadığını beyan etmiştir.

Referanslar

  1. Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315:801-10. https://doi.org/10.1001/jama.2016.0287
  2. Gül F, Arslantaş MK, Cinel İ, Kumar A. Changing definitions of sepsis. Turk J Anaesthesiol Reanim. 2017;45:129-38. https://doi.org/10.5152/TJAR.2017.93753
  3. Jarczak D, Kluge S, Nierhaus A. Sepsis-pathophysiology and therapeutic concepts. Front Med (Lausanne). 2021;8:628302. https://doi.org/10.3389/fmed.2021.628302
  4. Vincent JL, Marshall JC, Namendys-Silva SA, et al. Assessment of the worldwide burden of critical illness: the intensive care over nations (ICON) audit. Lancet Respir Med. 2014;2:380-6. https://doi.org/10.1016/S2213-2600(14)70061-X
  5. Vincent JL, Sakr Y, Sprung CL, et al. Sepsis in European intensive care units: results of the SOAP study. Crit Care Med. 2006;34:344-53. https://doi.org/10.1097/01.ccm.0000194725.48928.3a
  6. GBD 2021 Global Sepsis Collaborators. Global, regional, and national sepsis incidence and mortality, 1990-2021: a systematic analysis. Lancet Glob Health. 2025;13:e2013-26. https://doi.org/10.1016/S2214-109X(25)00356-0
  7. Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. Intensive Care Med. 2021;47:1181-247. https://doi.org/10.1007/s00134-021-06506-y
  8. Bottari G, Ranieri VM, Ince C, et al. Use of extracorporeal blood purification therapies in sepsis: the current paradigm, available evidence, and future perspectives. Crit Care. 2024;28:432. https://doi.org/10.1186/s13054-024-05220-7
  9. Malard B, Lambert C, Kellum JA. In vitro comparison of the adsorption of inflammatory mediators by blood purification devices. Intensive Care Med Exp. 2018;6:12. https://doi.org/10.1186/s40635-018-0177-2
  10. Kogelmann K, Jarczak D, Scheller M, Drüner M. Hemoadsorption by CytoSorb in septic patients: a case series. Crit Care. 2017;21:74. https://doi.org/10.1186/s13054-017-1662-9
  11. Schultz P, Schwier E, Eickmeyer C, Henzler D, Köhler T. High-dose CytoSorb hemoadsorption is associated with improved survival in patients with septic shock: A retrospective cohort study. J Crit Care. 2021;64:184-92. https://doi.org/10.1016/j.jcrc.2021.04.011
  12. Abdullayev R, Gul F, Bilgili B, Seven S, Cinel I. Cytokine adsorption in critically ill COVID-19 patients, a case-control study. J Intensive Care Med. 2022;37:1223-8. https://doi.org/10.1177/08850666221085185
  13. Schädler D, Pausch C, Heise D, et al. The effect of a novel extracorporeal cytokine hemoadsorption device on IL-6 elimination in septic patients: a randomized controlled trial. PLoS One. 2017;12:e0187015. https://doi.org/10.1371/journal.pone.0187015
  14. Becker S, Lang H, Vollmer Barbosa C, Tian Z, Melk A, Schmidt BMW. Efficacy of CytoSorb®: a systematic review and meta-analysis. Crit Care. 2023;27:215. https://doi.org/10.1186/s13054-023-04492-9
  15. Abbasi S, Naderi Z, Amra B, et al. Hemoperfusion in patients with severe COVID-19 respiratory failure, lifesaving or not? J Res Med Sci. 2021;26:34. https://doi.org/10.4103/jrms.JRMS_1122_20
  16. Premužić V, Babel J, Gardijan D, et al. Extracorporeal blood purification is associated with improvement in biochemical and clinical variables in the critically-ill COVID-19 patients. Ther Apher Dial. 2022;26:316-29. https://doi.org/10.1111/1744-9987.13730
  17. Brouwer WP, Duran S, Kuijper M, Ince C. Hemoadsorption with CytoSorb shows a decreased observed versus expected 28-day all-cause mortality in ICU patients with septic shock: a propensity-score-weighted retrospective study. Crit Care. 2019;23:317. https://doi.org/10.1186/s13054-019-2588-1
  18. Rugg C, Klose R, Hornung R, et al. Hemoadsorption with CytoSorb in septic shock reduces catecholamine requirements and in-hospital mortality: a single-center retrospective ‘genetic’ matched analysis. Biomedicines. 2020;8:539. https://doi.org/10.3390/biomedicines8120539
  19. Kara İ, Sargın M, Bayraktar YŞ, Eyiol H, Duman İ, Çelik JB. The use of vasoactive-inotropic score in adult patients with septic shock in intensive care. J Crit Intensive Care. 2019;10:23-30. https://doi.org/10.33381/dcbybd.2019.2057
  20. Epstein D, Badarni K, Bar-Lavie Y. Impact of haemoadsorption therapy on short term mortality and vasopressor dependency in severe septic shock with acute kidney injury: a retrospective cohort study. Antibiotics (Basel). 2024;13:1233. https://doi.org/10.3390/antibiotics13121233
  21. Hellman T, Uusalo P, Järvisalo MJ. Renal replacement techniques in septic shock. Int J Mol Sci. 2021;22:10238. https://doi.org/10.3390/ijms221910238
  22. Şenol EA, Karakoç E, Göçerler Z, Aydın OÖ, Yelken B. The efficacy of continuous renal replacement therapy and hemoabsorption treatments in COVID-19 patients in the intensive care unit: a retrospective evaluation. Turk J Intensive Care 2023;21:181-9. https://doi.org/10.4274/tybd.galenos.2022.30932

Telif hakkı ve lisans

Telif hakkı © 2025 Yazar(lar). Açık erişimli bu makale, orijinal çalışmaya uygun şekilde atıfta bulunulması koşuluyla, herhangi bir ortamda veya formatta sınırsız kullanım, dağıtım ve çoğaltmaya izin veren Creative Commons Attribution License (CC BY) altında dağıtılmıştır.

Nasıl atıf yapılır?

1.
Gül F, Tekin E, Çankaya E, Sabaz MS, Çiloğlu Iİ, Oktay BD, et al. Clinical efficacy of a protocol-based hemoadsorption therapy in patients with septic shock. Turk J Intensive Care. 2026;24(1):49-62. https://doi.org/10.63729/TJIC.2025.679